VTAK Acquires 19.98% Strategic Stake in AI-Enabled Aviation Company Fly Flyte, Inc.
MWN-AI** Summary
Catheter Precision, Inc. (NYSE American: VTAK) announced a significant strategic investment on February 17, 2026, acquiring a 19.98% stake in Fly Flyte, Inc. This FAA-certified regional aviation operator employs AI technologies and operates a fleet of Cirrus Vision Jets. Flyte is notable for providing revenue-generating services through its subsidiary, Ponderosa Air, LLC, which utilizes advanced safety features, including a whole-aircraft parachute system and Safe Return™ autonomous landing technology.
This investment immediately enhances VTAK’s exposure to the burgeoning regional air mobility sector, which is strategically poised for growth as the industry prepares for electric vertical takeoff and landing (eVTOL) commercialization. The deal underscores VTAK's commitment to diversifying its capital allocation into high-growth infrastructure sectors while maintaining strategic flexibility. Flyte's scalable fleet expansion potential allows VTAK to engage in a revenue-generating venture that operates in highly trafficked short-haul corridors—areas also targeted by future eVTOL initiatives.
CEO David Jenkins emphasized that the investment offers a critical foothold in a rapidly evolving industry by leveraging Flyte’s established operations and technology-driven optimization. With a capital-efficient model and ongoing revenue generation, Flyte is well-positioned to capitalize on market demands for premium short-haul connectivity.
Flyte's CEO, Marc Sellouk, reinforced the company's strategic aim of disciplined growth and scalability, highlighting the operational advantages provided by certified aircraft and robust regulatory compliance. The investment not only enhances VTAK’s portfolio but opens avenues for increased ownership and future monetization as Flyte scales.
This partnership is indicative of VTAK's broader strategy of investing in companies that offer tangible assets and clear paths to long-term value creation, positioning VTAK to benefit from the ongoing transformation of regional air travel.
MWN-AI** Analysis
The recent announcement of Catheter Precision, Inc. (NYSE: VTAK) acquiring a 19.98% stake in Fly Flyte, Inc. can be seen as a strategic move that positions VTAK favorably within the burgeoning aviation market, especially concerning AI-enabled technologies and regional air mobility solutions. This acquisition not only diversifies VTAK’s investment portfolio but also allows the company to tap into the accelerating demand for regional air transportation, which is expected to grow rapidly alongside advancements in electric vertical takeoff and landing (eVTOL) aircraft.
VTAK’s investment in Flyte is particularly astute given the immediate revenue generation and asset-backed nature of the airline's operations. Flyte operates a fleet of Cirrus Vision Jets and utilizes AI for operational optimizations, enhancing route efficiency and pricing strategies. This tangible operational backdrop creates a solid foundation for a scalable business model that can adapt and expand as the market evolves.
Investors should pay close attention to the implications of VTAK’s minority ownership, which preserves flexibility for future investment increases or monetization opportunities. The fact that Flyte is already generating revenue positions VTAK favorably compared to many technology firms still awaiting regulatory approval or operational commencement. Furthermore, as Flyte expands its fleet and operational capacity, VTAK stands to benefit not just from earnings but from a potential rise in equity value.
Looking forward, VTAK appears set to leverage this investment to navigate the complexities of the regional air mobility sector while accessing early revenue streams without relying solely on new technology development timelines. For investors, this represents a unique opportunity to gain exposure to a potentially lucrative market, with VTAK’s capital allocation strategy aligning with long-term industry trends. Conservative investors might appreciate the mixed asset exposure, while growth-minded stakeholders may find particular interest in the evolving dynamics of air mobility and AI integration.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Immediate Exposure to Revenue-Generating, Asset-Backed Regional Air Mobility Business Positioned Ahead of Anticipated Future Industry-wide eVTOL Commercialization
Strategic Investment Expands Capital Allocation into High-Growth Infrastructure with Scalable Fleet Expansion and Long-Term Equity Upside
Fort Mill, S.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) today announced a strategic minority investment in Fly Flyte, Inc. (“Flyte”), an FAA-certified regional aviation operator utilizing AI-enabled operations and a growing fleet of Cirrus Vision Jets.
Flyte conducts its flight operations through its wholly owned subsidiary, Ponderosa Air, LLC (FAA Air Carrier Certificate No. 1POA402M), operating under FAA 14 CFR Part 135, deploying Vision Jets across high-frequency short-haul regional routes where commercial airline capacity remains constrained. The company is generating revenue today with its fleet of Vision Jets, equipped with a proprietary whole-aircraft parachute system and Safe Return™ autonomous landing technology - advanced safety features that position the aircraft among the safest in the world.
The transaction provides VTAK immediate exposure to an operating aviation business supported by tangible assets, scalable fleet expansion capability and technology-driven operating optimization.
Transaction Overview
• VTAK acquires 19.98% equity ownership in Flyte, aligning long-term strategic upside
• Immediate exposure to one of the fastest-growing segments of private aviation
• Asset-backed, scalable fleet expansion model
• Preserves Flyte’s operating continuity and strategic control
• Creates optionality for increased ownership or future monetization
“The aviation sector is seeing accelerating investment in AI-enabled technologies designed to enhance mobility and drive operating efficiencies,” said David Jenkins, CEO and Chairman of VTAK. “Flyte combines certified operations, scalable fleet economics and technology-enabled optimization in a model built for disciplined growth and long-term value creation.”
Why Flyte
• Revenue-generating business operating today - not pre-revenue
• FAA Part 135 certified operator currently servicing multiple regions
• AI-enabled optimization across routing, pricing, dispatch and utilization
• Capital-efficient, asset-backed growth model
• Fleet of Vision Jets recognized for advanced integrated safety systems
Flyte expects disciplined expansion across select regional markets, targeting scalable revenue growth while maintaining capital efficiency.
Strategic Positioning Ahead of Future eVTOL Deployment
• Operates in the same short-haul regional markets targeted by eVTOL developers
• Generates operating data, route density and customer insights today
• Utilizes certified aircraft, trained crews and established regulatory infrastructure
• Provides current revenue exposure while preserving long-term strategic optionality
Significant capital has flowed into advanced air mobility and electric vertical takeoff and landing (eVTOL) companies, several of which trade at multi-billion-dollar public market valuations. While these companies represent long-term aviation innovation, certification and commercial deployment timelines could take years before commercially available.
Flyte operates today in the same corridors targeted for future electric aircraft integration. By leveraging certified aircraft and established infrastructure, Flyte generates active revenue, customer engagement and route density in markets attracting substantial long-term capital investment.
This positioning enables participation in the evolution of regional air mobility without reliance on future certification milestones, pairing current revenue generation with long-term structural upside.
Strategic Impact for VTAK
• Diversifies capital allocation into high-growth transportation infrastructure
• Adds exposure to AI-enabled aviation operations supported by tangible assets
• Creates potential embedded equity upside as Flyte scales
• Maintains disciplined minority position with strategic flexibility to increase ownership
“This investment provides VTAK shareholders exposure to an infrastructure-backed, revenue-generating aviation business positioned within one of the fastest-evolving segments of mobility,” Jenkins added. “Flyte’s certified operations and scalable fleet model allow us to participate in structural industry evolution while maintaining disciplined capital allocation.”
The investment reflects VTAK’s broader strategy of selectively deploying capital into operating businesses with scalable infrastructure, defensible technology and clear paths to long-term value creation.
Flyte Perspective
“Flyte is operating today with certified aircraft, established routes and scalable infrastructure,” said Marc Sellouk, CEO and Founder of Flyte. “Our model is rooted in disciplined execution, capital efficiency and measured growth, positioning us for the long-term evolution of regional air mobility.”
“Demand for premium short-haul connectivity is accelerating, and Flyte is purpose-built for this moment — combining real operations, real infrastructure and a scalable fleet strategy focused on execution and long-term value creation,” Sellouk added.
Additional Information
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities. Please refer to the Company’s Current Report on Form 8-K filed February 6, 2026 for additional details regarding the transaction, which is subject to customary closing conditions, including shareholder approval.
About Flyte
Flyte is a pioneering private aviation company transforming regional air travel through accessibility, convenience, and technology-driven innovation. Leveraging a seamless booking platform and an on-demand operating model, Flyte delivers a more efficient and scalable alternative to traditional private jet charter.
For more information, visit https://Flyte.travel.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company developing advanced solutions to improve the treatment of cardiac arrhythmias. The company focuses on bringing new technologies to market through collaboration with physicians and continuous product innovation.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to risks and uncertainties described in the Company’s filings with the SEC, available at www.sec.gov. The Company undertakes no obligation to update forward-looking statements except as required by law.
CONTACTS:
Investor Relations
973-691-2000
IR@catheterprecision.com
FAQ**
How does Catheter Precision Inc. VTAK plan to leverage its minority investment in Flyte to capitalize on the anticipated growth of the eVTOL market while maintaining a disciplined approach to capital allocation?
What metrics will Catheter Precision Inc. VTAK use to measure the success and scalability of Flyte’s operations as it continues to expand its fleet and service regional air mobility routes?
Given the current regulatory environment, how does Catheter Precision Inc. VTAK view the potential risks and challenges in scaling Flyte’s operations, especially with regard to FAA certification and compliance?
In what ways does Catheter Precision Inc. VTAK intend to support Flyte's AI-enabled operations to enhance efficiency and drive customer engagement as the regional air mobility market evolves?
**MWN-AI FAQ is based on asking OpenAI questions about Catheter Precision Inc. (NYSE: VTAK).
NASDAQ: VTAK
VTAK Trading
-7.79% G/L:
$1.4847 Last:
246,927 Volume:
$1.51 Open:
